Dr. Staecker is the Principal Investigator for the first gene therapy trial (CGF166) to restore hearing in patients with severe-to-profound hearing loss. Dr. Staecker’s clinical practice is focused on Neurotology, and Otology. Dr. Staecker is also the Principal Investigator for the Kansas City investigative site for a Phase 2b Study of SPI-1005 to reduce the Incidence, Severity, and Duration of Acute Noise Induced Hearing Loss (NIHL). Dr. Staecker’s research focuses on developing treatments for hearing loss. Currently, the main effort of his research lab is focused on developing gene therapy for the treatment of an inner ear disease. Dr. Staecker is also involved in clinical studies on cochlear implants and a totally implanted hearing aid. Dr. Staecker has published numerous articles and book chapters and is the Director Division of Otology/Neurotology-Dept of Otolaryngology- Head and Neck Surgery; Tenured Professor, Dept of Otolaryngology- Head and Neck Surgery; Tenured Professor, Dept of Hearing and Speech; Tenured Professor, Dept of Neurosurgery.